FDA’s Purple Book Launches Categorization Era For Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Modeled on “Orange Book” reference guide for small molecule drugs, agency’s new publication will be a repository of exclusivity and interchangeability information.
You may also be interested in...
FTC Biosimilars Workshop: Second Time’s The Charm?
Having failed to significantly influence the design of the federal approval pathway, the Commission is hoping to have an impact on product naming and state substitution laws.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.